Analyst Insight: Politicians are increasing pressure on pharmaceutical manufacturers to reduce drug prices. While many policies are still in the proposal phase, we can expect new regulatory action in 2026 that will further complicate the pricing environment. Pharmaceutical manufacturers will work to shift the discourse from political debate to practical patient access strategies.

Three major policy and market forces are shaping the pharmaceutical landscape in 2026: new pricing rules, drastically expanding direct-to-consumer (DTC) channels and a renewed focus on domestic manufacturing.

The Trump Administration’s Most Favored Nation (MFN) executive order ties U.S. prices for certain drugs to the lowest price in comparable nations. This EO may lack legal enforceability, but policymakers will likely enact formal regulations in 2026. Regardless of the exact form the rules take, incremental rulemaking will create new administrative burdens for manufacturers while having minimal impact on patient costs. In many cases, Medicaid already pays less than the MFN price, and any price change is unlikely to affect what patients pay at the pharmacy counter. 

Instead, this policy may slow down new drug availability outside the U.S. because manufacturers must be more selective about where to launch products. The complexity of U.S. pricing models may start to spread globally. Other nations, such as Germany, are already adopting opaque rebate and contracting practices to shield their true net prices from being used in American comparisons.

The Trump Administration is also creating a direct-to-consumer (DTC) website called Trump RX. This platform will enable patients to buy discounted prescriptions from participating manufacturers. This initiative will increase drug access for some patients — those who are uninsured, have high deductibles or whose insurance won’t cover their medication — but it won’t meaningfully reduce drug prices. The vast majority of consumers will be able to buy their prescriptions at a much lower cost through their insurance. 

Additional changes to drug distribution and pricing infrastructure will be necessary to move the needle on affordability. 

The federal government is offering incentives to pharma manufacturers that reshore their manufacturing operations in the U.S. Many companies have agreed to invest in domestic infrastructure in return for waived tariffs, but much of the momentum comes from market demand and accelerated drug discovery. 

Many companies are expanding their manufacturing capacity to keep up with the demand for GLP-1 drugs. Advances in AI and personalized medicine are fueling a new innovation cycle that demands sophisticated, high-end manufacturing capabilities that are located near research centers and patient populations. These new facilities are long-term investments that will continue regardless of who is in the White House. 

Resource Link: https://www.modeln.com/

Outlook: Pharma manufacturers don’t want to manage the gross-to-net bubble (the difference between list prices and net prices); they want to get lifesaving medications into the hands of patients. Over the next couple of years, the industry will move past list-price optics to focus on strategies that accelerate patient access, streamline distribution and reduce administrative delays.